URICOSURIC AGENTS IN THE TREATMENT OF GOUT

BY

G. D. KERSLEY AND A. R. GIBBS

Royal National Hospital for Rheumatic Diseases, Bath, Somerset

During the past 2½ years an attempt has been made to assess the relative value and toxicity of various uricosuric agents.

Previous Investigations

Kersley, Cook, and Tovey (1958) reported the therapeutic value of G.28315 (sulphinpyrazone), a phenylbutazone derivative now known as Anturan (Geigy), in a group of fifteen patients with gout in a clinical trial lasting 3 to 8 months. Benemid and Urelim (Ward, Blenkinsop and Co.), were also given in selected cases. The results, as shown by estimations of the urinary uric acid excretion and the serum uric acid, are summarized in the Table (Rows 1-4). Anturan was the most efficacious drug, although the other two also had a definite uricosuric effect. Intermittent administration 3 days per week was not effective. It was found that the use of 3-5 g. aspirin as an analgesic completely inhibited the effect of Anturan in the doses given (Table, Row 5).

Present Study

Material.—32 patients were all suffering from typical gout, with raised serum uric acid levels and normal differential agglutination tests. The average age was 56 years. The average age at onset was 41 years (range 22 to 71), fourteen being aged 25 to 35 years at onset. There were 27 men and five women. Thirteen patients gave a definite family history of gout.

Medication.—Each patient had a period on both Anturan and Urelim. Nine had Anturan and two Urelim continuously for more than a year, and the remaining 21 received the two drugs alternately. In eighteen cases Anturan and Urelim were tried together and separately, and in the same group a third drug, Zoxazolamine (Flexin; 2-amino-5-chlorobenzoxazole), was also tried separately.

The chemical structure of all these drugs is shown in the Figure.

In view of our previous finding that 3-5 g. aspirin given simultaneously with Anturan completely
inhibited the uricosuric effect of the latter, the results were observed of giving aspirin or paracetamol* to four patients who were taking Anturan regularly, and to one who was taking Zoxazolamine.

Further investigations included the effects of Anturan and Zoxazolamine on the serum cholesterol and prothrombin times.

**Results**

Anturan.—The patients who continued on Anturan continued to do well, the serum uric acid levels remaining the same at the end of one year as they had been at the end of 3 months. In the patients shown in the Table (Row 4) in whom the average serum uric acid level was 7·1 mg./100 ml. before treatment and 4·8 mg./100 ml. at the end of 3 months, the level was 4·9 mg./100 ml. after one year.

Anturan \+ Urelim.—Eighteen patients who were taking Anturan 400 mg. daily regularly for some months were given in addition 1·5 g. Urelim daily for one week, and the Urelim was continued at the same dosage for a further week while the Anturan was reduced to 200 mg. daily. The average daily serum uric acid level was 3·5 mg./100 ml. on Anturan alone, fell to 2·9 mg./100 ml. when Urelim was added, and rose to 3·1 mg./100 ml. when the Anturan was reduced (Table, Rows 7-9). Meanwhile, the average daily urinary uric acid excretion rose from 776 to 806, and then fell to 654 mg./100 ml. The results suggest that Urelim had an adjuvant effect in combination with Anturan.

Urelim.—This drug was also tried alone in seven patients, who received 1·5 g. daily. Their average urinary uric acid excretion (which had been 608 mg./day before treatment) rose to 880 mg./day, and the serum uric acid level (7·8 mg./100 ml. before treatment) fell to 6·4 mg./100 ml. (Table, Row 6). Thus Urelim was not so effective alone as with Anturan.

---

**Table**

**RESULTS OF PREVIOUS INVESTIGATION AND PRESENT STUDY**

<table>
<thead>
<tr>
<th>Source</th>
<th>Drugs under Trial</th>
<th>No. of Cases in Group Tested</th>
<th>Before Start of Treatment</th>
<th>Effects of Single Drug</th>
<th>Effects of Drug or Drugs on Trial</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Drug</td>
<td>Dosage</td>
<td>Urinary Uric Acid Excretion (mg./day)</td>
<td>Serum Uric Acid Excretion (mg./100ml.)</td>
<td>Serum Uric Acid Excretion (mg./day)</td>
</tr>
<tr>
<td>Kersley and others, 1958</td>
<td>Benemid (I and II)</td>
<td>1·5 g.</td>
<td>7</td>
<td>581</td>
<td>7·6</td>
</tr>
<tr>
<td>(Tables I-IV)</td>
<td>Anturan (I and II)</td>
<td>400 mg.</td>
<td>13</td>
<td>551</td>
<td>7·8</td>
</tr>
<tr>
<td></td>
<td>Anturan (I)</td>
<td>800 mg.</td>
<td>7</td>
<td>581</td>
<td>7·6</td>
</tr>
<tr>
<td></td>
<td>Anturan for 3 months (III)</td>
<td>400 mg.</td>
<td>7</td>
<td>540</td>
<td>7·1</td>
</tr>
<tr>
<td></td>
<td>Anturan + Aspirin (IV)</td>
<td>3·5 g.</td>
<td>9</td>
<td>576</td>
<td>7·7</td>
</tr>
<tr>
<td></td>
<td>Urelim</td>
<td>1·5 g.</td>
<td>7</td>
<td>608</td>
<td>7·8</td>
</tr>
<tr>
<td></td>
<td>Anturan</td>
<td>400 mg.</td>
<td>18</td>
<td>776</td>
<td>3·5</td>
</tr>
<tr>
<td>Results of Present Study</td>
<td>Anturan + Urelim</td>
<td>400 mg.</td>
<td>18</td>
<td>770</td>
<td>3·3</td>
</tr>
<tr>
<td></td>
<td>Zoxazolamine</td>
<td>1·5 g.</td>
<td>18</td>
<td>808</td>
<td>1·9</td>
</tr>
</tbody>
</table>

* 4·9 after 1 year.
**Zoxazolamine.**—This drug was originally produced as a relaxant, depressing the subcortical and spinal pathways (Lancet, 1956). A dose of 0.25 g. was said to promote uricosuria by Burns, Yü, Berger, and Gutman (1958) and Reed, Feichtmeir, and Willett (1958), and its effect was therefore compared with that of Anturan and Urelim. The same eighteen patients who had been taking Anturan 400 mg. daily regularly for some months were given Zoxazolamine 1.5 g. daily for one week. The average daily serum uric acid level fell from 3.5 to 3.3 mg./100 ml., but at the same time the average daily urinary uric acid excretion fell from 776 to 712 mg. (Table, Row 10).

**Addition of Analgesics**

*Aspirin.*—Four patients who were taking Anturan 400 mg. daily regularly were given 3.5 g. aspirin in addition, and the average daily urinary uric acid excretion fell from 770 to 637 mg. (Table, Row 11).

One patient who had taken Zoxazolamine 1.5 g. for one week was given 3.5 g. aspirin in addition for a further week, and the daily urinary uric acid excretion fell from 808 to 580 mg., while the serum uric acid level rose from 1.9 to 3.8 mg./100 ml. (Table, Row 12).

*Paracetamol* (N-acetyl-p- amino-phenol; Panadol, Panok).—The four patients on Anturan who had been tested with additional aspirin were also tested with additional paracetamol 3.5 g. daily, and the average daily urinary uric acid excretion fell only very slightly from 770 to 756 mg. (Table, Row 13).

The question of analgesics is important in a case presenting both gout and osteo-arthritis, and it appears that paracetamol can be combined with a uricosuric agent without significantly inhibiting the effect of the latter.

**Effect of Uricosuric Agents on Blood Coagulation and Serum Cholesterol.**

Thompson, Mikkelsen, and Willis (1959), who reviewed the uricosuric effect of various anticoagulants, found that ethylbicumacetate (Tromexan), bihydroxycoumarin, and anisindione produced uricosuria.

Kohn and Prozan (1959), who found that a series of patients with acute myocardial infarction had serum uric acid levels above 6 mg./100 ml., suggested that the exhibition of uricosuric drugs might afford some protection against coronary atherosclerosis.

Gertler and White (1954) has suggested that high serum uric acid levels might encourage the deposition of cholesterol, so that a lowering of the serum uric acid level might improve the prognosis by counteracting this process.

Serum cholesterol levels and prothrombin times were estimated in our gouty patients while under treatment with uricosuric agents.

*Serum Cholesterol.*—There is a wide variation in normal levels which average about 200 mg. per cent., the range according to Juergens and Achor (1959) being 150-250 mg. per cent. Treatment by restriction of fats and the use of oestrogens or thyroid extract has been advised for patients with levels above 250 mg. per cent.

Our eighty serum cholesterol estimations showed no direct correlation between the levels of cholesterol and uric acid. In thirty estimations on patients in whom the average serum uric acid level was below 3.5 mg./100 ml., the average serum cholesterol was 241 mg. per cent., and in twelve estimations on patients in whom the average serum uric acid level was above 4.5 mg./100 ml., the average serum cholesterol was 232 mg. per cent. In four cases for which figures were available before and after treatment, however, there was a tendency for the serum cholesterol to fall as the serum uric acid fell:

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Serum Uric Acid (mg./100 ml.)</th>
<th>Serum Cholesterol (mg. per cent.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td>After</td>
<td>Before</td>
</tr>
<tr>
<td>1</td>
<td>7.3</td>
<td>3.6</td>
</tr>
<tr>
<td>2</td>
<td>5.2</td>
<td>2.8</td>
</tr>
<tr>
<td>3</td>
<td>7.9</td>
<td>4.5</td>
</tr>
<tr>
<td>4</td>
<td>4.2</td>
<td>3.4</td>
</tr>
</tbody>
</table>

The average serum cholesterol in eighteen cases was 250 mg. per cent. before treatment, 242 after Anturan, and 219 after Zoxazolamine.

*Prothrombin Time.*—Eighty estimations (shown as a percentage of the pre-treatment time) were carried out on the eighteen patients who were treated with Anturan and Zoxazolamine; the average was 99 per cent. after Anturan and 97 per cent. after Zoxazolamine. When series of estimations carried out on individual patients were reviewed, there appeared to be a slight initial fall when the patient first took Zoxazolamine, followed by a rapid return to normal within a week or two in the majority of cases.

**Subject Improvement and Side-Effects**

All patients claimed that they had improved rather than deteriorated during the 2 years, in that
they were now having fewer attacks of gout and often had less general stiffness.

Eleven patients preferred Anturan. The reason was that they felt less “tired” and had less general stiffness and interval pain, probably because of the slight anti-inflammatory effect of this preparation.

Two patients preferred Urelim. One had developed boils while taking Anturan, but the white cell count remained normal and the boils did not recur on re-administration of Anturan. The other thought he had fewer attacks of gout while taking Urelim.

Of 21 patients who were transferred from Anturan to Zoxazolamine, five stated that they felt a “little tired” while taking the Zoxazolamine, one felt “muzzy” during the first 3 days of treatment, and one had slight headaches. Eight were equally well with either drug, but ten preferred Anturan and three Zoxazolamine.

Two patients had slight dyspepsia, but not sufficient to make one consider stopping medication during a minimum period of 6 weeks.

Course of the Disease

During the first 6 weeks of treatment there was a tendency to increase in the frequency of attacks of gout, but after this period there was marked lessening of frequency and severity. During this first 6 weeks, colchicine 0·5 mg. was given three times a day, and, if in spite of this, attacks occurred, phenylbutazone 600 mg. daily for 2 days was always completely successful in checking them.

In six instances there was a definite softening or decrease in the size of the tophi, and two patients reported some change in this direction after only 6 weeks’ therapy.

Summary

32 patients with typical gout have been observed during treatment with uricosuric agents for at least 2 years, in continuation of the studies reported by Kersley and others (1958).

Anturan and Urelim were found to have a satisfactory effect both alone and in combination, and a similar effect was produced by the administration of Zoxazolamine.

Aspirin inhibited the uricosuric effect of all these drugs, but paracetamol did not do so.

Estimations were also made of the serum cholesterol and prothrombin times, with the idea of testing the theory that serum cholesterol and uric acid levels are related.

All the patients treated felt subjective benefit, although some felt better on one drug, and some on another. Toxic effects were rare and extremely slight, but on the whole Anturan was the favourite drug and the least toxic.

Because the numbers of patients who could be tested with each drug varied, and only a few could be observed daily for months in hospital, these results cannot collectively be subjected to statistical analysis. They show clearly, however, the great value, potency, and safety of the newer uricosuric drugs in the treatment of gout, with perhaps Anturan leading the field. Further work is required on the combined use of these drugs—e.g. the potentiation of Anturan by Urelim—and in particular on the degree of inhibition exerted by various dosages of other drugs, especially of the aspirin type. The possible importance of dosage inhibition is emphasized by the recent paper of Yu and Gutman (1959).

We are indebted to Dr. W. S. Stoddart of Messrs. Geigy Pharmaceutical Co. Ltd. for supplying the Anturan, to Dr. J. M. Simister of Messrs. Ward Blenkinsop and Co. for the Urelim, and the McNeil Laboratories Inc. of Philadelphia for the Zoxazolamine.

REFERENCES
Lancer (1956). 1, 561.

Agents uricosuriques dans la goutte

RéSUMÉ
A la suite des travaux rapportés par Kersley, Cook, et Tovey (1958), on a observé 32 malades atteints de goutte classique et traités par des agents uricosuriques pendant au moins deux ans. Anturan et Urelim ont donné des résultats satisfaisants, aussi bien seuls qu’en combinaison, et on a obtenu un effet similaire avec Zoxazolamine.

L’aspirine inhibait l’effet uricosurique de tous ces produits, mais le paracetamol ne l’inhibait pas.

On a procédé aussi à des déterminations du cholestérol sérique et du temps de prothrombine, pour vérifier la théorie qu’il y avait un rapport entre les taux de cholestérol sérique et d’acide urique.

Tous les malades traités ont accusé une amélioration subjective, bien que certains d’entre eux en préféraient un produit à un autre. Des effets toxiques étaient rares et légers; en général, l’Anturan était le favori et le moins toxique.

Comme le nombre de malades traités par chaque produit variait et peu d’entre eux pouvaient être observés tous les jours pendant des mois à l’hôpital, ces
URICOSURIC AGENTS IN GOUT

rезультаты, коллективно, не подвергаются статистическому анализу. Они демонстрируют, тем не менее, значительную ценность, эффективность и безопасность более новых урикосурических средств в лечении гиперпуринемии, включая Anturan, на их фоне. Другие работы необходимы для изучения комбинированного использования этих средств (например, потенцирование Anturan на Urelim) и особенно в отношении степени ингибирования, вызванных различными дозами некоторых препаратов, особенно таких, как аспирин. Возможное значение дозы в ингибировании подчеркнуто недавно в работе Yu и Gutman (1959).

Se realizaron también determinaciones de colesterol sérico y tiempo de protrombina, con la idea de comprobar la teoría de la relación entre los niveles de colesterol sérico y ácido úrico.

Todos los enfermos tratados experimentaron mejoría subjetiva, aunque algunos la apreciaron más con un determinado fármaco mientras que otros reaccionaron mejor a otro diferente. Efectos tóxicos fueron raros y leves, en general. Anturan fue el más preferido y menos tóxico.

Como el número de enfermos tratados con cada fármaco varió, y solamente unos pocos pudieron ser observados diariamente durante meses en hospital, estos resultados no se pueden someter colectivamente a análisis estadístico. De todas formas, es claramente manifiesto el gran valor, la potencia y la inocuidad de los últimos agentes uricosúricos introducidos en la terapéutica de la gota, con el Anturan quizás a la cabeza de ellos. Es necesario más trabajo sobre el uso combinado de estos productos (p.e. la potenciación del Anturan por el Urelim), y particularmente sobre el grado de inhibición ejercida por diferentes dosis de otros fármacos, especialmente del tipo de la aspirina. La posible importancia de la dosis en inhibición es subrayada por el reciente trabajo de Yu y Gutman (1959).
Uricosuric Agents in the Treatment of Gout

G. D. Kersley and A. R. Gibbs

doi: 10.1136/ard.19.4.351

Updated information and services can be found at:
http://ard.bmj.com/content/19/4/351.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/